Literature DB >> 8333146

The biology of haematogenous metastasis in human uveal malignant melanoma.

I W McLean.   

Abstract

Using data on 4726 cases of uveal melanoma collected by the Registry, of Ophthalmic Pathology at the Armed Forces Institute of Pathology, my co-workers and I have been studying the biology of haematogenous metastasis. We have developed methods for evaluating separately the relationships between prognostic factors and cure-rate and median survival time for uncured patients. We have discovered that size of the tumour and size of the largest nucleoli in the cells of the uveal melanomas related equally to cure-rate and median survival time. The presence of Callender's epitheloid-type cells in the tumour and increased patient age had little effect on cure-rate but dramatically reduced the median survival time.

Entities:  

Mesh:

Year:  1993        PMID: 8333146     DOI: 10.1007/bf01606450

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histopathol        ISSN: 0174-7398


  14 in total

1.  Proportion cured and mean log survival time as functions of tumour size.

Authors:  J W Gamel; I W McLean; S H Rosenberg
Journal:  Stat Med       Date:  1990-08       Impact factor: 2.373

2.  Adjustment of long-term survival rates for deaths due to intercurrent disease.

Authors:  S J Cutler; L M Axtell; D Schottenfeld
Journal:  J Chronic Dis       Date:  1969-12

3.  The natural course of untreated uveal melanomas.

Authors:  L E Zimmerman; I W McLean
Journal:  Doc Ophthalmol       Date:  1980-12-15       Impact factor: 2.379

4.  Computerized histologic assessment of malignant potential: a method for determining the prognosis of uveal melanomas.

Authors:  J W Gamel; I W McLean; R A Greenberg; L E Zimmerman; S J Lichtenstein
Journal:  Hum Pathol       Date:  1982-10       Impact factor: 3.466

5.  Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture.

Authors:  I J Fidler
Journal:  Cancer Res       Date:  1990-10-01       Impact factor: 12.701

6.  Lymphocytic infiltration in uveal malignant melanoma.

Authors:  P O de la Cruz; C S Specht; I W McLean
Journal:  Cancer       Date:  1990-01-01       Impact factor: 6.860

7.  Is breast cancer a curable disease? A study of 14,731 women with breast cancer from the Cancer Registry of Norway.

Authors:  L E Rutqvist; A Wallgren; B Nilsson
Journal:  Cancer       Date:  1984-04-15       Impact factor: 6.860

8.  Biologic distinctions between cure and time to death in 2892 patients with intraocular melanoma.

Authors:  J W Gamel; I W McLean; J B McCurdy
Journal:  Cancer       Date:  1993-04-01       Impact factor: 6.860

9.  Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.

Authors:  P H Quax; G N van Muijen; E J Weening-Verhoeff; L R Lund; K Danø; D J Ruiter; J H Verheijen
Journal:  J Cell Biol       Date:  1991-10       Impact factor: 10.539

10.  Distribution of survival times of 12,000 head and neck cancer patients who died with their disease.

Authors:  R F Mould; T Hearnden; M Palmer; G C White
Journal:  Br J Cancer       Date:  1976-08       Impact factor: 7.640

View more
  11 in total

Review 1.  Tumor plasticity allows vasculogenic mimicry, a novel form of angiogenic switch. A rose by any other name?

Authors:  M J Bissell
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

2.  The molecular classification of uveal melanocytic lesions: an important discovery in context.

Authors:  Robert Folberg
Journal:  J Mol Diagn       Date:  2010-06-03       Impact factor: 5.568

3.  Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study.

Authors:  ShriHari S Kadkol; Amy Y Lin; Vivian Barak; Inna Kalickman; Lu Leach; Klara Valyi-Nagy; Dibyen Majumdar; Suman Setty; Andrew J Maniotis; Robert Folberg; Jacob Pe'er
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-03       Impact factor: 4.799

Review 4.  Vasculogenic mimicry and tumor angiogenesis.

Authors:  R Folberg; M J Hendrix; A J Maniotis
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

5.  Tumor cell plasticity in uveal melanoma: microenvironment directed dampening of the invasive and metastatic genotype and phenotype accompanies the generation of vasculogenic mimicry patterns.

Authors:  Robert Folberg; Zarema Arbieva; Jonas Moses; Amin Hayee; Tone Sandal; Shrihari Kadkol; Amy Y Lin; Klara Valyi-Nagy; Suman Setty; Lu Leach; Patricia Chévez-Barrios; Peter Larsen; Dibyen Majumdar; Jacob Pe'er; Andrew J Maniotis
Journal:  Am J Pathol       Date:  2006-10       Impact factor: 4.307

6.  Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry.

Authors:  A J Maniotis; R Folberg; A Hess; E A Seftor; L M Gardner; J Pe'er; J M Trent; P S Meltzer; M J Hendrix
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

7.  Molecular regulation of vasculogenic mimicry in human uveal melanoma cells: role of helix-loop-helix Id2 (inhibitor of DNA binding 2).

Authors:  Fan Su; Bin Li; Jian Wang; Xiaolin Xu; Ruojin Ren; Liaoqing Li; Fei Gao; Xiaochao Liu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-11-29       Impact factor: 3.117

8.  Modeling the behavior of uveal melanoma in the liver.

Authors:  Robert Folberg; Lu Leach; Klara Valyi-Nagy; Amy Y Lin; Marsha A Apushkin; Zhuming Ai; Vivian Barak; Dibyen Majumdar; Jacob Pe'er; Andrew J Maniotis
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-07       Impact factor: 4.799

9.  Effect of Genistein on vasculogenic mimicry formation by human uveal melanoma cells.

Authors:  Rihong Cong; Qingmin Sun; Li Yang; Haijuan Gu; Ying Zeng; Bin Wang
Journal:  J Exp Clin Cancer Res       Date:  2009-09-07

10.  Immunohistochemical expression of melan-A and tyrosinase in uveal melanoma.

Authors:  Bruno F Fernandes; Alexandre N Odashiro; Vinicius S Saraiva; Patrick Logan; Emilia Antecka; Miguel N Burnier
Journal:  J Carcinog       Date:  2007-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.